Table 1.
Open in new tab

Patients’ and disease characteristics

VariableN = 60
Sex, female, n (%)43 (71.7%)
Age, mean (SD)61.1 (13.8)
BMI, mean (SD)28.3 (5.7)
Primary diagnosis, n (%)
RA19 (31.7%)
SLE15 (25%)
AAV11 (18.3%)
Myositis6 (10%)
Other9 (15%)
Disease duration, years, mean (SD)6.5 (5.1)
Concurrent treatment (at sampling), n (%)
HCQ17 (28.3%)
MTX16 (26.7%)
MMF7 (11.7%)
JAKi1 (1.7%)
CYC1 (1.7%)
Belimumab1 (1.7%)
Glucocorticoids, n (%)34 (56.7%)
Glucocorticoids median dose, mg (IQR)5 (3.25-5)
Comorbidities, n (%)
Diabetes11 (18.3%)
Hypertension15 (26.7%)
Dyslipidemia16 (26.7%)
COPD/Asthma4 (6.7%)
CVD9 (15%)
CKD3 (5%)
Current cancer3 (5%)
Number of administered vaccines, n (%)
28 (13.3%)
340 (66.7%)
412 (20%)
RTX cycles, median (IQR)4 (2.25-6.75)
RTX cumulative dose, grams, median (IQR)7 (4.25-12)
Last vaccine to sampling, days, median (IQR)179 (117-221.5)
Last RTX infusion to sampling, days, median (IQR)139 (113-176.5)
Timing of last vaccine between RTX cycles, n (%)
0–4 months34 (56.7%)
5–6 months26 (43.3%)
Previous COVID-19 (before sampling), n (%)12 (20%)
Hospitalization for COVID-19 (before sampling), n (%)3/12 (25%)
COVID-19 infection (post sampling), n (%)20 (33.3%)
Hospitalization for COVID-19 (post sampling), n (%)3/20 (15%)
VariableN = 60
Sex, female, n (%)43 (71.7%)
Age, mean (SD)61.1 (13.8)
BMI, mean (SD)28.3 (5.7)
Primary diagnosis, n (%)
RA19 (31.7%)
SLE15 (25%)
AAV11 (18.3%)
Myositis6 (10%)
Other9 (15%)
Disease duration, years, mean (SD)6.5 (5.1)
Concurrent treatment (at sampling), n (%)
HCQ17 (28.3%)
MTX16 (26.7%)
MMF7 (11.7%)
JAKi1 (1.7%)
CYC1 (1.7%)
Belimumab1 (1.7%)
Glucocorticoids, n (%)34 (56.7%)
Glucocorticoids median dose, mg (IQR)5 (3.25-5)
Comorbidities, n (%)
Diabetes11 (18.3%)
Hypertension15 (26.7%)
Dyslipidemia16 (26.7%)
COPD/Asthma4 (6.7%)
CVD9 (15%)
CKD3 (5%)
Current cancer3 (5%)
Number of administered vaccines, n (%)
28 (13.3%)
340 (66.7%)
412 (20%)
RTX cycles, median (IQR)4 (2.25-6.75)
RTX cumulative dose, grams, median (IQR)7 (4.25-12)
Last vaccine to sampling, days, median (IQR)179 (117-221.5)
Last RTX infusion to sampling, days, median (IQR)139 (113-176.5)
Timing of last vaccine between RTX cycles, n (%)
0–4 months34 (56.7%)
5–6 months26 (43.3%)
Previous COVID-19 (before sampling), n (%)12 (20%)
Hospitalization for COVID-19 (before sampling), n (%)3/12 (25%)
COVID-19 infection (post sampling), n (%)20 (33.3%)
Hospitalization for COVID-19 (post sampling), n (%)3/20 (15%)
Table 1.
Open in new tab

Patients’ and disease characteristics

VariableN = 60
Sex, female, n (%)43 (71.7%)
Age, mean (SD)61.1 (13.8)
BMI, mean (SD)28.3 (5.7)
Primary diagnosis, n (%)
RA19 (31.7%)
SLE15 (25%)
AAV11 (18.3%)
Myositis6 (10%)
Other9 (15%)
Disease duration, years, mean (SD)6.5 (5.1)
Concurrent treatment (at sampling), n (%)
HCQ17 (28.3%)
MTX16 (26.7%)
MMF7 (11.7%)
JAKi1 (1.7%)
CYC1 (1.7%)
Belimumab1 (1.7%)
Glucocorticoids, n (%)34 (56.7%)
Glucocorticoids median dose, mg (IQR)5 (3.25-5)
Comorbidities, n (%)
Diabetes11 (18.3%)
Hypertension15 (26.7%)
Dyslipidemia16 (26.7%)
COPD/Asthma4 (6.7%)
CVD9 (15%)
CKD3 (5%)
Current cancer3 (5%)
Number of administered vaccines, n (%)
28 (13.3%)
340 (66.7%)
412 (20%)
RTX cycles, median (IQR)4 (2.25-6.75)
RTX cumulative dose, grams, median (IQR)7 (4.25-12)
Last vaccine to sampling, days, median (IQR)179 (117-221.5)
Last RTX infusion to sampling, days, median (IQR)139 (113-176.5)
Timing of last vaccine between RTX cycles, n (%)
0–4 months34 (56.7%)
5–6 months26 (43.3%)
Previous COVID-19 (before sampling), n (%)12 (20%)
Hospitalization for COVID-19 (before sampling), n (%)3/12 (25%)
COVID-19 infection (post sampling), n (%)20 (33.3%)
Hospitalization for COVID-19 (post sampling), n (%)3/20 (15%)
VariableN = 60
Sex, female, n (%)43 (71.7%)
Age, mean (SD)61.1 (13.8)
BMI, mean (SD)28.3 (5.7)
Primary diagnosis, n (%)
RA19 (31.7%)
SLE15 (25%)
AAV11 (18.3%)
Myositis6 (10%)
Other9 (15%)
Disease duration, years, mean (SD)6.5 (5.1)
Concurrent treatment (at sampling), n (%)
HCQ17 (28.3%)
MTX16 (26.7%)
MMF7 (11.7%)
JAKi1 (1.7%)
CYC1 (1.7%)
Belimumab1 (1.7%)
Glucocorticoids, n (%)34 (56.7%)
Glucocorticoids median dose, mg (IQR)5 (3.25-5)
Comorbidities, n (%)
Diabetes11 (18.3%)
Hypertension15 (26.7%)
Dyslipidemia16 (26.7%)
COPD/Asthma4 (6.7%)
CVD9 (15%)
CKD3 (5%)
Current cancer3 (5%)
Number of administered vaccines, n (%)
28 (13.3%)
340 (66.7%)
412 (20%)
RTX cycles, median (IQR)4 (2.25-6.75)
RTX cumulative dose, grams, median (IQR)7 (4.25-12)
Last vaccine to sampling, days, median (IQR)179 (117-221.5)
Last RTX infusion to sampling, days, median (IQR)139 (113-176.5)
Timing of last vaccine between RTX cycles, n (%)
0–4 months34 (56.7%)
5–6 months26 (43.3%)
Previous COVID-19 (before sampling), n (%)12 (20%)
Hospitalization for COVID-19 (before sampling), n (%)3/12 (25%)
COVID-19 infection (post sampling), n (%)20 (33.3%)
Hospitalization for COVID-19 (post sampling), n (%)3/20 (15%)
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close